IKT
Inhibikase Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.67
+3.09%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$0.11
- Revenue estimate
- $187.5K
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.11
- EPS estimate
- -$0.11
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- +5.7%
- Revenue beats (12Q)
- 0
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.11 | -$0.11 | Miss -2.33% | — |
| May 12, 2026 | -$0.10 | -$0.10 | In line | — |
| Mar 26, 2026 | -$0.12 | -$0.09 | Beat 25.00% | — |
| Nov 14, 2025 | -$0.13 | -$0.13 | In line | — |
| Aug 14, 2025 | -$0.09 | -$0.11 | Miss -22.22% | — |
| Mar 26, 2025 | -$0.10 | -$0.63 | Miss -530.00% | — |
| Nov 14, 2024 | -$0.38 | -$0.65 | Miss -71.05% | — |
| Aug 14, 2024 | -$0.58 | -$0.66 | Miss -13.79% | — |
| May 15, 2024 | -$0.79 | -$0.73 | Beat 7.59% | — |
| Nov 14, 2023 | -$1.12 | -$0.86 | Beat 23.21% | $79.6K |
| Aug 14, 2023 | -$0.92 | -$1.11 | Miss -20.65% | $116.4K |
| Nov 14, 2022 | -$0.18 | -$1.08 | Miss -500.00% | $7.3K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026